Vivus cuts 20 jobs as Qsymia sales disappoint again
This article was originally published in Scrip
Executive Summary
Vivus earned $6.4m in third quarter 2013 net product revenue from sales of the prescription weight loss drug Qsymia (phentermine and topiramate), which is less than a $1m gain since the second quarter when Qsymia revenue totaled $5.5m and bested first quarter sales by $1.3m.